1. Home
  2. SNY vs GEOS Comparison

SNY vs GEOS Comparison

Compare SNY & GEOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNY
  • GEOS
  • Stock Information
  • Founded
  • SNY 1994
  • GEOS 1980
  • Country
  • SNY France
  • GEOS United States
  • Employees
  • SNY N/A
  • GEOS N/A
  • Industry
  • SNY Biotechnology: Pharmaceutical Preparations
  • GEOS Industrial Machinery/Components
  • Sector
  • SNY Health Care
  • GEOS Industrials
  • Exchange
  • SNY Nasdaq
  • GEOS Nasdaq
  • Market Cap
  • SNY 116.5B
  • GEOS 72.9M
  • IPO Year
  • SNY N/A
  • GEOS 1997
  • Fundamental
  • Price
  • SNY $48.70
  • GEOS $14.03
  • Analyst Decision
  • SNY Buy
  • GEOS
  • Analyst Count
  • SNY 2
  • GEOS 0
  • Target Price
  • SNY $62.50
  • GEOS N/A
  • AVG Volume (30 Days)
  • SNY 2.1M
  • GEOS 481.6K
  • Earning Date
  • SNY 07-24-2025
  • GEOS 08-07-2025
  • Dividend Yield
  • SNY 3.31%
  • GEOS N/A
  • EPS Growth
  • SNY 39.56
  • GEOS N/A
  • EPS
  • SNY 5.45
  • GEOS N/A
  • Revenue
  • SNY $48,817,552,946.00
  • GEOS $116,542,000.00
  • Revenue This Year
  • SNY $3.39
  • GEOS N/A
  • Revenue Next Year
  • SNY $7.05
  • GEOS N/A
  • P/E Ratio
  • SNY $17.56
  • GEOS N/A
  • Revenue Growth
  • SNY N/A
  • GEOS N/A
  • 52 Week Low
  • SNY $45.80
  • GEOS $5.51
  • 52 Week High
  • SNY $60.12
  • GEOS $18.99
  • Technical
  • Relative Strength Index (RSI)
  • SNY 43.32
  • GEOS 63.11
  • Support Level
  • SNY $47.64
  • GEOS $12.80
  • Resistance Level
  • SNY $49.37
  • GEOS $17.21
  • Average True Range (ATR)
  • SNY 0.68
  • GEOS 1.83
  • MACD
  • SNY 0.14
  • GEOS 0.13
  • Stochastic Oscillator
  • SNY 30.56
  • GEOS 60.06

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

About GEOS Geospace Technologies Corporation (Texas)

Geospace Technologies Corp is engaged in designing and manufacturing seismic instruments and non-seismic equipment used in the oil and gas industry. The company has three different segments: oil and gas markets, adjacent markets, and emerging markets. The oil and gas markets segment, which accounts for the majority of the company's revenue, includes traditional exploration products, wireless exploration products, and reservoir characterization products and services. The adjacent markets business is closely tied to the oil and gas markets and includes imaging products and industrial products. The company operates globally across Asia, Canada, Europe, the United States, South America, Mexico, and other regions with a majority of its revenue being generated within the United States.

Share on Social Networks: